Medical Advocates
HIV Infection/Disease
  Dyslipidemia  
General Reports
Clinical Management




 




 

 
Adipose Tissue  Main Page   Main New/Newsworthy Home Page  
Last Update: February 03, 2012
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader.

General Reports
       

        Journal Papers, Abstracts, and Commentaries

 
FULL-TEXT ARTICLE
HIV and HAART-Associated Dyslipidemia.
Feeney ER, Mallon PW.
 Open Cardiovasc Med J. 2011;5:49-63.
Paper

The Effect of polymorphisms in candidate genes on the Long-Term Risk of Lipodystrophy
and Dyslipidemia in HIV-infected Caucasians Starting Antiretroviral Therapy.
Marzocchetti A, Schwarz J, DI Giambenedetto S,   et al
AIDS Res Hum Retroviruses. 2011 May 20.
Abstract

FULL-TEXT ARTICLE
 Dyslipidemia in AIDS patients on highly active antiretroviral therapy.
Nery MW, Martelli CM, Turchi MD.
Braz J Infect Dis. 2011 Apr;15(2):151-5.
 Paper

Dyslipidemia related to antiretroviral therapy.
EstradaV, Portilla J.
AIDS Rev. 2011 Jan-Mar;13(1):49-56.
 Abstract

High Molecular Weight Form of Adiponectin in Antiretroviral Drug-induced
Dyslipidemia in HIV-Infected Japanese Individuals Based on in vivo and
in vitro Analyses.
Minami R, Yamamoto M, Takahama S, Ando H, et al
Intern Med. 2009;48(20):1799-875
 Abstract

Association of APOC3 Polymorphisms with Both Dyslipidemia and Lipoatrophy in
HAART-Receiving Patients.
Bonnet E, Bernard J, Fauvel J, Massip P
AIDS Res Hum Retroviruses. 2008 Feb 1
Abstract
 
Protease Inhibitor-Associated Dyslipidemia in HIV-Infected Patients Is Strongly Influenced by
the APOA5-1131T->C Gene Variation.
 Guardiola M, Ferre R, Salazar J, et al
Clin Chem. 2006 Aug 3;
Abstract
 
Alterations in liver, muscle, and adipose tissue insulin sensitivity in men with HIV
infection and dyslipidemia.
Reeds DN, Yarasheski KE, Fontana L
Am J Physiol Endocrinol Metab. 2005 Aug 23
 Abstract
 
Dyslipidaemia and cardiovascular risk in HIV infection.
 Kulasekaram R, Peters BS, Wierzbicki AS. 
Curr Med Res Opin. 2005 Nov;21(11):1717-25
 Abstract
 
Lipodystrophy and Dyslipidemia Among Patients Taking First-Line, World Health Organization-
Recommended Highly Active Antiretroviral Therapy Regimens in Western India.
Pujari SN, Dravid A, Naik E, et al 
J Acquir Immune Defic Syndr. 2005 Jun 1;39(2):199-202
 Abstract
 
Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy
(HAART) on cardiovascular risk and life expectancy
 Grover SA, Coupal L, Gilmore N, Mukherjee J.
 Am J Cardiol. 2005 Mar 1;9
 Abstract
 
Endoplasmic Reticulum Stress Links Dyslipidemia to Inhibition of Proteasome
Activity and Glucose Transport by HIV Protease Inhibitors.
Parker RA, Flint OP, Mulvey R, et al
 Mol Pharmacol. 2005 Mar 8;
 Abstract
 
Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV
lipodystrophy: a model of 'systemic steatosis'
Balasubramanyam A, Sekhar RV, Jahoor F, et al  
Curr Opin Lipidol. 2004 Feb;15(1):59-67.
 Abstract
 
Cardiovascular Implications of HIV-associated Dyslipidemic Lipodystrophy.
Sekhar RV, Jahoor F, Pownall HJ, et al 
Curr Atheroscler Rep. 2004 May;6(3):173-9.
 Abstract

Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.
Calza L, Manfredi R, Chiodo F.et al 
J Antimicrob Chemother. 2003 Nov 25
Abstract

Alterations in lipid kinetics in men with HIV-dyslipidemia.
Reeds DN, Mittendorfer B, Patterson BW
 Am J Physiol Endocrinol Metab 2003 May 13;
 Abstract

  

        Conference Reports, Abstracts, and Posters

 
Changes in Markers of Atherogenic Dyslipidemia, Inflammation, and Platelet Activation with
Treatment with Pravastatin, Fenofibrate, or the Combination: Results from the ACTG A5087 Team
C Fichtenbaum, TM Yeh, S Evans, et al
(15 CROI)
Abstract
 
Gender and Race/Ethnicity Differences in Dyslipidemia among HIV-infected Patients
Participating in the Fat Redistribution and Metabolic Change Cohort Study
D Wohl, J Currier, R Scherzer, et al
(13 CROI)
Abstract
 
POSTER
The Effect of Polymorphism of the MDR-1 Gene on the Long-term Risk of Lipodystrophy and
Dyslipidemia in HIV-infected Patients Starting ART
A De Luca, S Di Giambenedetto, J Schwarz, et al 
(13 CROI)
PDF Poster     Abstract

Dyslipidemia, Osteopenia, and Changes in Body Habitus in HIV-infected Women
 E Schoenbaum    
(11 CROi)
 Abstract

Dyslipemia and Hyperinsulinemia in HIV Patients on HAART  
 (41 ICAAC)
Abstract

  

Clinical Management
       
        Journal Papers, Abstracts, and Commentaries
 
 
Ritonavir-induced lipoatrophy and dyslipidaemia is reversed by the anti-inflammatory drug
leflunomide in a PPAR-γ-dependent manner.
 Mencarelli A, Francisci D, Renga B,  et al
Antivir Ther. 2012 Jan 25.
Abstract

FULL-TEXT PDF ARTICLE
 Dyslipidemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the
Spanish VACH cohort.
 Estrada V, Geijo P, Fuentes-Ferrer M, et al  
BMC Womens Health. 2011 Aug 4;11(1):36
Paper

Combination of Niacin and Fenofibrate with Lifestyle Changes Improves Dyslipidemia
and Hypoadiponectinemia in HIV Patients on Antiretroviral Therapy: Results of
"Heart Positive," a Randomized, Controlled Trial.
Balasubramanyam A, Coraza I, Smith EO,  et al
J Clin Endocrinol Metab. 2011 May 11
 Abstract

Dyslipidemia and lipid management in HIV-infected patients.
Lo J.
Curr Opin Endocrinol Diabetes Obes. 2011 Feb 3
 Abstract

Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients.
Singh S, Willig JH, Mugavero MJ,M., et al
 Clin Infect Dis. 2010 Dec 28.
 Abstract

Treatment of dyslipidemia in HIV-infected patients.
Sekhar RV, Balasubramanyam A.
Expert Opin Pharmacother. 2010 May 20
 Abstract

A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable
background antiretroviral therapy: ACTG 5206.
 Tungsiripat M, Kitch D, Glesby MJ, et al
AIDS. 2010 May 21
 Abstract

Evaluation and Pharmacologic Management of the HIV-Infected Patient With Dyslipidemia.
Hardwicke RL, Lewis ST, Grimes RM.
J Assoc Nurses AIDS Care. 2010 Mar 18.
 Abstract

Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors:
a randomized trial.
Aslangul E, Assoumou L, Bittar R, et al
AIDS. 2009 Oct 15
 Abstract

HIV-associated dyslipidaemia: pathogenesis and treatment.
Oh J, Hegele RA 
Lancet Infect Dis. 2007 Dec;7(12):787-96.
 Abstract
 
Treatment of HIV-associated dyslipidemia: a role for omega-3 fatty acids.
Metroka CE, Truong P, Gotto AM Jr.  
AIDS Read. 2007 Jul;17(7):362-4, 367-73.
 Abstract
 
Management of Dyslipidemia and Other Cardiovascular Risk Factors in HIV-Infected Patients:
Case-based Review.
Aberg JA.
Top HIV Med. 2006 Oct-Nov;14(4):134-9.
Abstract
 
Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected
patients with poor response to statins.
Negredo E, Molto J, Puig J, et al  
AIDS. 2006 Nov 14;20(17):2159-2164.
 Abstract
 
Effectiveness and tolerance of atorvastatin for antiretroviral therapy-secondary dyslipemia.
 Soler A, Deig E, Guil J, Rodriguez-Martin M, Guelar A, Pedrol E.
Med Clin (Barc). 2006 Jul 15;127(7):250-2
 Abstract

Exercise training in HIV-1-infected individuals with dyslipidemia and lipodystrophy.
 Terry L, Sprinz E, Stein R, Medeiros NB, Oliveira J, Ribeiro JP. 
Med Sci Sports Exerc. 2006 Mar;38(3):411-7.
 Abstract
 
  Strategies for management and treatment of dyslipidemia in HIV/AIDS.
 Sax PE. 
AIDS Care. 2006 Feb;18(2):149-157
 Abstract
 
  Management of dyslipidemia in patients with complicated metabolic syndrome.
 Davidson MH.  
 Am J Cardiol. 2005 Aug 22;96(4A):22-5.
 Abstract
 
  Treatment of dyslipidaemia in HIV-infected persons.
 Manuel O, Thiebaut R, Darioli R, Tarr PE.
 Expert Opin Pharmacother. 2005 Aug;6(10):1619-45.
Abstract
 
  The role of diet, exercise and smoking in dyslipidaemia in HIV-infected patients with
lipodystrophy.
 Shah M, Tierney K, Adams-Huet B, et al
HIV Med. 2005 Jul;6(4):291-8.
 Abstract
   
  Lipid lowering effects of statins and fibrates in the management of HIV
dyslipidemias associated ith antiretroviral therapy in HIV clinical practice.
 Visnegarwala F, Maldonado M, Sajja P, et al 
J Infect. 2004 Nov;49(4):283-90.
Abstract
 
  Effects of pravastatin on lipoproteins and endothelial function in patients receiving
human immunodeficiency virus protease inhibitors.
 Stein JH, Merwood MA, Bellehumeur JL ,et al.
Am Heart J. 2004 Apr;147(4):713.
 Abstract
 
  Reduction of fat accumulation and lipid disorders by individualized light aerobic
training in human immunodeficiency virus infected patients with lipodystrophy
and/or dyslipidemia.
 Thoni GJ, Fedou C, Brun JF,  et al
 Diabetes Metab 2002 Nov;28(5):397-404
 Abstract
   
  Evaluation and Management of Dyslipidemia in Patients with HIV Infection.
Green ML
J Gen Intern Med 2002 Oct;17(10):797-810
 Abstract
   
  A pilot study of the safety and efficacy of cholestin in treating HIV-related
dyslipidemia.
 Keithley JK, Swanson B, Sha BE, et al.
Nutrition 2002 Feb;18(2):201-204
 Abstract
 
        Conference Reports, Abstracts, and Posters
 
 
Changes in Markers of Atherogenic Dyslipidemia, Inflammation, and Platelet Activation with
Treatment with Pravastatin, Fenofibrate, or the Combination: Results from the ACTG A5087
 Team
C  Fichtenbaum, T M Yeh, S Evans, et al
 (15 CROI)
 Abstract
 
Effect of interventions to improve dyslipidaemia
 M vd Valk, N Friis-Møller, C Sabin, et al
(8th Int Congress on Drug Therapy in HIV Infection)
 Abstract
 
Rosuvastatin in the treatment of dyslipidaemia in HIV patients
 S Das, M Boothby, C Stradling , et al
(8th Int Congress on Drug Therapy in HIV Infection)
 Abstract
 
Dyslipidaemia in an Asian Population following Treatment for 2 Years with 5
Different Protease Inhibitor-containing Regimens: The HIV-NAT Cohort
 C Duncombe , S Kerr , A Avihingsanon, et al
 (12 CROI)
 Abstract
 
Protease Inhibitors, Apolipoprotein C-III Polymorphisms and Atherogenic
Dyslipidemia in HIV
 A Foulkes, D Wohl, P Tebas, et al
 (12 CROI)
 Abstract

Atorvastatin in the treatment of dyslipaemia related to antiretroviral therapy (ART)
 E Pedrol, J Guil, M Rodriguez
(15IAC)
 Abstract

Adipose Tissue  Main Page   Main New/Newsworthy Home Page  

Dyslipidemia